Shire to Study ADHD Drug in Preschool-Age Children
the Psychiatry Advisor take:
The FDA has asked drug maker Shire to conduct pediatric clinical studies to investigate the potential use of lisdexamfetamine dimesylate (Vyvanse) to treat attention deficit hyperactivity disorder (ADHD) in kids aged 4 to 5 years -- an age group notoriously understudied in pharmaceutical clinical trials.
Shire is in the midst of designing the three clinical trials of lisdexamfetamine dimesylate. The three studies include a pharmacokinetic study to help determine appropriate dosing, and evaluate safety and tolerability; an efficacy and safety study; and an open-label study to evaluate long-term safety. The first trial is slated to start in the first half of 2015.
FDA Asks Shire to Conduct Trials of Vyvanse in Preschool-Age Children
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Link Identified Between Cured Meat and Mania in Bipolar Disorder
- Suicide Attempts Associated With Sleep and Circadian Rhythm Disturbances in Bipolar Disorder
- First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes
- Early Risk Factors for Bipolar Disorder Found in Offspring of BD Parents
- Probiotics, Depression, and the Role of Inflammation
- The Opioid System: The Foundation for Social Risk and Reward
- Correctional Psychiatry: Challenges and Rewards
- Those Left Behind: Working With Suicide-Bereaved Families
- The Impact of Deafness on Hallucinations and Delusions
- Is Mandatory Reporting of Child Maltreatment in the Best Interests of the Child?
- Nutrition Tips for Physicians: Staying Healthy During Busy Days
- Mental Health Problems in Adolescents With HIV: Overview & Expert Interview
- Should Physicians Play a Role in Minimizing the Societal Cost of Medical Care?
- Digital Cognitive Behavioral Therapy Effective for Individuals With Insomnia
- How Do Medical Scribes Reduce EHR Documentation Burden for Physicians?